NGM Bio Appoints Siobhan Nolan Mangini as Chief Financial Officer
May 27 2020 - 4:05PM
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology
company focused on developing transformative therapeutics for
patients, today announced the appointment of Siobhan Nolan Mangini
as Chief Financial Officer (CFO). In her role as CFO, which will
take effect on July 13, 2020, Ms. Nolan Mangini will oversee
finance, business development and investor relations at
NGM.
“We are thrilled to welcome Siobhan to the NGM executive team.
Her rich and diverse background across the healthcare landscape
make her an ideal addition as NGM’s Chief Financial Officer,
particularly as our lead asset, aldafermin for the treatment of
non-alcoholic steatohepatitis, or NASH, advances toward late-stage
clinical development, and our other novel metabolic, ophthalmic and
oncologic product candidates also progress in development,” said
David J. Woodhouse, Ph.D., Chief Executive Officer at NGM.
“Siobhan’s deep financial expertise, coupled with her broad
leadership experience spanning a myriad of critical business
functions, will enable her to have a far-reaching impact across our
company as she leads the refinement and implementation of
strategic, operational and financial planning to position NGM for
long-term growth and success.”
“I am delighted to join David and the NGM team,” said Ms. Nolan
Mangini. “I’m incredibly impressed by the rich scientific heritage
of NGM, its many accomplishments to date, and its unwavering
commitment and passion to bring important new medicines to
patients. I believe NGM has many attributes that make it a true
industry standout and will enable the company to continue to
thrive. As NGM progresses its clinical stage pipeline in multiple
therapeutic areas, along with its earlier stage research programs,
I look forward to collaborating with everyone at NGM to fulfill our
bold ambitions. I am excited to contribute to this mission-driven
journey by leading NGM’s finance, business development and
strategic planning efforts, and to support the alignment of the
company’s research and development execution.”
Ms. Nolan Mangini most recently served as President and CFO of
Castlight Health, a publicly traded San Francisco-based healthcare
technology company. She joined Castlight in 2012 and assumed roles
of increasing responsibility, ultimately being appointed CFO in
2016 followed by her additional appointment as President in 2019.
At Castlight, Ms. Nolan Mangini was responsible for a wide range of
functions including strategic and corporate planning, finance,
investor relations, people, legal, real estate, customer support
and business operations. During her tenure at Castlight, Ms. Nolan
Mangini supported the enterprise SAAS company’s growth from a few
thousand users to 20 million users and scale up of its customer
base, including large employers, Fortune 500 companies and channel
partners. She was deeply involved in the establishment of
significant payer partnerships, the company’s initial public
offering and the execution of a transformative acquisition. Prior
to joining Castlight, Ms. Nolan Mangini worked as a management
consultant at Bain & Company, specializing in the health care
and private equity practices. She began her career at the Henry J.
Kaiser Family Foundation as a financial associate responsible for
managing the allocation of the foundation’s endowment.
Ms. Nolan Mangini has a Master of Business Administration from
the Graduate School of Business at Stanford University, a Master of
Public Administration from the Kennedy School of Government at
Harvard University and a Bachelor of Science in Economics from the
Wharton School at the University of Pennsylvania.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on developing novel
therapeutics based on scientific understanding of key biological
pathways underlying cardio-metabolic, liver, oncologic and
ophthalmic diseases. We leverage our biology-centric drug discovery
approach to uncover novel mechanisms of action and generate
proprietary insights that enable us to move rapidly
into proof-of-concept studies and deliver
potential first-in-class medicines to patients. At NGM,
we aspire to operate one of the most productive research and
development engines in the biopharmaceutical industry, with
multiple programs in clinical development. Visit us
at www.ngmbio.com for more information.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as “will,” “believe,” “look forward,”
“advance,” “progress,” “position,” “leads” and similar expressions
(as well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. These statements include those related
to: the timing of Ms. Nolan Mangini joining as NGM’s CFO and her
ability to impact NGM’s growth and success; advancement of
aldafermin toward late-stage development and other clinical and
preclinical development progress; NGM’s potential long-term growth
and success; and other statements that are not historical fact.
Because such statements deal with future events and are based on
NGM’s current expectations, they are subject to various risks and
uncertainties, and actual results, performance or achievements of
NGM could differ materially from those described in or implied by
the forward-looking statements in this press release. These risks
and uncertainties include, without limitation, risks and
uncertainties associated with: the inherent uncertainty of
management changes and NGM’s ability to retain its senior
management team; the costly and time-consuming pharmaceutical
product development process and the uncertainty of clinical
success, including risks related to failure or delays in
successfully enrolling or completing clinical studies, the risk
that the results obtained to date in NGM’s clinical trials may not
be indicative of results obtained in pivotal or other late-stage
trials, and the risk that NGM’s ongoing or future clinical studies
in humans may show that aldafermin is not a tolerable and effective
treatment for NASH patients; the evolving effects of the COVID-19
pandemic, which may significantly impact (i) our business and
operations, including out of our headquarters in the San Francisco
Bay Area and our clinical trial sites, as well as the business or
operations of our manufacturers, contract research organizations or
other third parties with whom we conduct business, (ii) our ability
to access capital, and (iii) the value of our common stock; the
time-consuming and uncertain regulatory approval process; NGM’s
reliance on third-party manufacturers for aldafermin and its other
product candidates; the sufficiency of NGM’s cash resources and
need for additional capital; and other risks and uncertainties
affecting NGM and its development programs, including those
described under the caption “Risk Factors” in NGM’s quarterly
report on Form 10-Q for the quarter ended March 31, 2020 and future
filings and reports that NGM makes from time to time with the
United States Securities and Exchange Commission. Except as
required by law, NGM assumes no obligation to update these
forward-looking statements, or to update the reasons if actual
results differ materially from those anticipated in the
forward-looking statements.
Investor
Contact:Sylvia Wheeler and Alexandra
Santosswheeler@wheelhouselsa.comasantos@wheelhouselsa.comir@ngmbio.com |
Media
Contact:Liz Melonemedia@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Apr 2023 to Apr 2024